

20. L. R. Zieske, *J. Exp. Bot.* **57**, 1501 (2006).
21. S. T. Cole et al., *Nature* **393**, 537 (1998).
22. M. L. Burts, W. A. Williams, K. DeBord, D. M. Missiakas, *Proc. Natl. Acad. Sci. U.S.A.* **102**, 1169 (2005).
23. L. Y. Gao et al., *Mol. Microbiol.* **53**, 1677 (2004).
24. E. Martz, *Trends Biochem. Sci.* **27**, 107 (2002).
25. W. R. Pearson, D. J. Lipman, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 2444 (1988).
26. W. R. Pearson, *Methods Enzymol.* **183**, 63 (1990).
27. We thank H. Madhani and the Cox laboratory for the critical reading of this manuscript, and members of the Cox, A. Sil, and E. Brown laboratories for helpful discussion. This investigation was supported by NIH under Ruth L. Kirschstein National Research Service Award A105155 to P.A.C. This work was supported by NIH grants A163302 and A151667. J.S.C. gratefully acknowledges the support of the Sandler Family Supporting Foundation and the W. M. Keck Foundation.

Supporting Online Material

www.sciencemag.org/cgi/content/full/313/5793/1632/DC1

Materials and Methods

SOM Text

Figs. S1 to S3

Tables S1 and S2

12 June 2006; accepted 13 July 2006

10.1126/science.1131167

An Alternative Bactericidal Mechanism of Action for Lantibiotic Peptides That Target Lipid II

Hester E. Hasper,¹ Naomi E. Kramer,^{1,2} James L. Smith,³ J. D. Hillman,⁴ Cherian Zachariah,⁵ Oscar P. Kuipers,² Ben de Kruijff,¹ Eefjan Breukink^{1*}

Lantibiotics are polycyclic peptides containing unusual amino acids, which have binding specificity for bacterial cells, targeting the bacterial cell wall component lipid II to form pores and thereby lyse the cells. Yet several members of these lipid II–targeted lantibiotics are too short to be able to span the lipid bilayer and cannot form pores, but somehow they maintain their antibacterial efficacy. We describe an alternative mechanism by which members of the lantibiotic family kill Gram-positive bacteria by removing lipid II from the cell division site (or septum) and thus block cell wall synthesis.


In less than eight decades, Alexander Fleming's discovery of penicillin in 1928 catalyzed a multibillion-dollar pharmaceutical industry, spawned a plethora of antibiotics, and saved countless lives. However, human deaths stemming from infectious diseases have steadily reemerged in parallel with the rise of antibiotic-resistant pathogens, and medical researchers urgently need to develop new classes of antibiotics. Here, we report our findings on an alternative mechanism for bactericidal activity in members of the lantibiotic family of small peptides. No protein receptor is required for the bactericidal activity of this class of antibiotics. These molecules kill bacteria by sequestering the essential cell wall biosynthetic molecule lipid II from the sites where bacterial cell wall synthesis occurs.

The cell wall of bacteria forms a large scaffold of linear polymers of alternating amino sugars that are cross-linked via peptide bridges (the peptidoglycan layer). This layer is essential for survival. Its composition is quite uniform throughout the eubacteria, and consequently cell wall biosynthesis is an important target for anti-

biotics (1, 2). One of the key molecules in bacterial peptidoglycan synthesis is lipid II, because it is essential for the transport of cell wall subunits across the bacterial cytoplasmic membrane (fig. S1A). This highly dynamic molecule is present in all eubacteria in relatively small amounts (3). Lipid II is assembled on the cytoplasmic side of the bacterial membrane and is composed of one peptidoglycan subunit linked via a pyrophosphate on a polyisoprenoid membrane anchor [GlcNAc-MurNAc-pentapeptide (fig. S1B)]. Subsequently, lipid II is transported across the plasma membrane, where it delivers its cargo to a multienzyme complex for polymerization and insertion into the preexisting cell wall (4).

The glycopeptide vancomycin binds specifically to the C-terminal D-Ala-D-Ala sequence of the pentapeptide of lipid II, thereby (i) preventing the binding of penicillin-binding proteins (PBPs) that are responsible for the polymerization and integration of the peptidoglycan subunits into the cell wall and (ii) consequently inhibiting cell wall synthesis, ultimately leading to cell death. The group of small molecules known as lantibiotics also targets lipid II but acts by distinct mechanisms (5). Members of this family of antimicrobial peptides are characterized by the posttranslational addition of lanthionine rings (6–8). The best-known lantibiotic, nisin (fig. S1C), contains five lanthionine rings and kills bacteria by targeted pore formation (9, 10). Recent structural studies show that the lanthionine rings A and B form a baseball glove-like structure (the pyrophosphate cage) that binds the pyrophosphate of lipid II (11). This formation is followed by the assembly of nisin into a pore complex, together with lipid II, that has a stoichiometry of eight nisins and four lipid IIs (12). Yet there are nisin mutants (in the hinge region comprising residues 20 to 22) that do not have the ability to form pores but are still potent antibiotics (12, 13). Likewise, other related lantibiotics with similar A/B ring structures [for instance, mutacin 1140 (fig. S1D)] also do not form pores (fig. S2). However, these lantibiotics are very efficient bactericides as well (14). We have discovered that lantibiotics with an N-terminal pyrophosphate cage have an alternative lipid II–dependent bactericidal mechanism.

Fig. 1. Lipid II segregation caused by lantibiotics visualized by fluorescence microscopy. (A) Nisin in action. After the addition of 2 to 4 μ l of a 2 mM nisin solution, the peptide started to diffuse into the field of view from the bottom right corner. This image is a snapshot of three vesicles that have either not yet encountered nisin (vesicle a), just encountered nisin (vesicle b), or already been exposed to nisin for some time (vesicle c). Scale bar, 60 μ m. (B) GUV doped with NBD-labeled lipid II before treatment with mutacin 1140. (C) Mutacin 1140–induced segregation of NBD-labeled lipid II. (D) Snapshot of a GUV treated with mutacin 1140 just at the onset of the lipid II segregation; the interior remains black. The green fluorescence of the NBD-labeled lipid II and the red fluorescence of Texas Red were sequentially detected with the use of two lasers.



¹Department of Biochemistry of Membranes, Bijvoet Center for Biomolecular Research, Institute of Biomembranes, Utrecht University, Padualaan 8, 3584 CH, Utrecht, Netherlands. ²Department of Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Post Office Box 14, 9750 AA, Haren, Netherlands. ³Department of Biological Sciences, Post Office Box GY, Mississippi State University, Mississippi State, MS 39762, USA. ⁴Oragenics Incorporated, 13700 Progress Boulevard, Alachua, FL 32615, USA. ⁵Banyon Biomarkers, 12085 Research Drive, Alachua, FL 32615, USA.

*To whom correspondence should be addressed. E-mail: e.j.breukink@chem.uu.nl

We visualized the effect of nisin on giant unilamellar vesicles (GUVs) doped with fluorescently labeled lipid II. The fluorescence of the 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD)-labeled lipid II was initially spread homogeneously over the GUV surface, and the fluorescence of the soluble marker Texas Red remained extracellular (Fig. 1A). After the addition of nisin, the GUVs first filled up with red fluorescence as a result of pore formation (Fig. 1), and the green fluorescence originating from NBD-labeled lipid II then clearly segregated in the membrane (Fig. 1). Thus, wild-type nisin caused the segregation of lipid II in model membranes after the formation of pores.

The addition of mutacin 1140 to NBD-labeled lipid II-doped GUVs (Fig. 1B) resulted in hot spots of lipid II fluorescence appearing within the membranes (Fig. 1C). Mutacin 1140 did not increase the permeability of the membrane, because red fluorescence was not seen inside the GUVs (Fig. 1D and fig. S2). A hinge-region mutant of nisin [(N20PM21P)-nisin] that is a potent bacterial killer but is unable to form pores (12, 13) gave results similar to those of mutacin 1140 (fig. S3). Comparable fluorescent patches were observed on the GUVs (fig. S4), when fluorescently labeled nisin [fluorescein was attached to the C terminus, where it does not affect the activity of the lantibiotic (fig. S5)] was added to GUVs doped with unlabeled lipid II. Hence, the patches contained both the lantibiotics and lipid II. These results suggest that the sequestration of lipid II is involved in the mode of action of these lantibiotics.

Peptidoglycan synthesis of bacteria has been shown to take place at defined positions on the bacterial membrane. During cell division, large amounts of peptidoglycan are synthesized at the septum and, during cell elongation (in the case of a rod-shaped cell), peptidoglycan synthesis is organized in helical threads along the longitudinal axis of the cell (15). This synthesis coincides with the localization of lipid II in vivo to the

septum of *Bacillus subtilis* and in helical threads along the long axis of this bacterium, as visualized with fluorescently labeled vancomycin (15). If lipid II cannot colocalize with peptidoglycan synthesis, then cell wall formation is inhibited, and bacteria are killed.

We tested whether the lantibiotic-induced lipid II segregation seen in GUVs occurs in bacteria. As a marker for the location of lipid II in vivo, we used fluorescently labeled vancomycin as described in (15). Labeled vancomycin bound to GUVs only when they contained wild-type lipid II, and it did not cause any segregation (Fig. 2A), demonstrating that it did not change the localization of the randomly dispersed lipid II. Like the results described by Daniel and Errington (15), the vancomycin label clearly revealed pools of lipid II in the septum (Fig. 2, B and C), as well as in helical threads along the long axis of *Bacillus* cells. After the addition of fluorescently labeled nisin to these bacteria, a different lipid II distribution pattern was observed (Fig. 2, D and E). The fluorescence was absent from the septum (Fig. 2D), and the helical threads were not seen. Instead, the fluorescence originating from the nisin molecules appeared to be clustered in patches on the bacterial membranes, as in the observations in the GUVs. The effects were observed for more than 80% of the bacteria (fig. S6). Similar results were obtained with fluorescently labeled (N20PM21P)-nisin (fig. S7), and control experiments showed that, under the conditions used, the fluorescently labeled nisins bound only to lipid II (fig. S8). Similar patches could be observed upon treatment of *Lactococcus lactis* IL1403 with fluorescently labeled nisin, demonstrating that the lipid II sequestration by nisin was not limited to rod-shaped bacteria (fig. S9). These results demonstrate that nisin segregates lipid II into abnormal domains not only in vitro but also in vivo.

Our results provide an explanation for previously observed effects of staphylococcin T (a

lantibiotic similar to mutacin 1140) on *Micrococcus* sp. (16), which may now be explained by an uncoupling between cell wall synthesis and membrane synthesis during cell division. Recently, it has been shown that lantibiotics similar to mutacin 1140 (such as gallidermin and epidermin) are able to form pores only in model membranes composed of short-chain phospholipids that form thin membranes (17). Their high level of antibacterial activity can now be explained by the sequestration mechanism described here.

Based on these experiments, we propose that nisin and a broad range of at least 10 other lantibiotics (18–20) having similar A/B ring structures displace lipid II from its functional location in Gram-positive bacteria. The lantibiotics bind to the pyrophosphate of lipid II, and their effect depends on the combination of the length of the peptide and the thickness of the lipid bilayer. Lantibiotics resembling nisin kill the bacteria primarily by forming pores together with lipid II. Those that bear the pyrophosphate cage, but are short and cannot span a bacterial bilayer to form pores, still remove lipid II from its functional location. This sequestering effect is a distinct mode of bactericidal activity that is currently known only in the lantibiotics which does not appear to have any known candidate resistance mechanisms.

References and Notes

1. A. L. Koch, *Clin. Microbiol. Rev.* **16**, 673 (2003).
2. C. H. Walsh, *Nat. Rev. Microbiol.* **1**, 65 (2003).
3. Y. van Heijenoort, M. Gomez, M. Derrien, J. Ayala, J. van Heijenoort, *J. Bacteriol.* **174**, 3549 (1992).
4. W. Vollmer, J. V. Holtje, *Curr. Opin. Microbiol.* **4**, 625 (2001).
5. E. Breukink, B. de Kruijff, *Nat. Rev. Drug Discovery* **5**, 321 (2006).
6. B. Li *et al.*, *Science* **311**, 1464 (2006).
7. L. Xie *et al.*, *Science* **303**, 679 (2004).
8. C. Chatterjee, M. Paul, L. L. Xie, W. A. van der Donk, *Chem. Rev.* **105**, 633 (2005).
9. E. Breukink *et al.*, *Science* **286**, 2361 (1999).
10. H. Brotz *et al.*, *Mol. Microbiol.* **30**, 317 (1998).
11. S. T. D. Hsu *et al.*, *Nat. Struct. Mol. Biol.* **11**, 963 (2004).
12. H. E. Hasper, B. de Kruijff, E. Breukink, *Biochemistry* **43**, 11567 (2004).
13. I. Wiedemann *et al.*, *J. Biol. Chem.* **276**, 1772 (2001).
14. H. Morency, M. Mota-Meira, G. LaPointe, C. Lacroix, M. C. Lavoie, *Can. J. Microbiol.* **47**, 322 (2001).
15. R. A. Daniel, J. Errington, *Cell* **113**, 767 (2003).
16. B. Furmanek *et al.*, *J. Appl. Microbiol.* **87**, 856 (1999).
17. R. R. Bonelli, T. Schneider, H. G. Sahl, I. Wiedemann, *Antimicrob. Agents Chemother.* **50**, 1449 (2006).
18. P. A. Wescombe, J. R. Tagg, *Appl. Environ. Microbiol.* **69**, 2737 (2003).
19. T. Stein *et al.*, *J. Bacteriol.* **184**, 1703 (2002).
20. O. McAuliffe, R. P. Ross, C. Hill, *FEMS Microbiol. Rev.* **25**, 285 (2001).
21. H.E.H. and N.E.K. were supported by the Nederlandse Organisatie voor Wetenschappelijk and the Onderzoek Stichting voor de Technische Wetenschappen (grant 349-5257). We thank P. van den Bogaard and D. Sakharov for their help with the confocal fluorescence experiments.

Supporting Online Material

www.sciencemag.org/cgi/content/full/313/5793/1636/DC1
Materials and Methods

Figs. S1 to S9

References

11 May 2006; accepted 26 July 2006
10.1126/science.1129818

Fig. 2. Nisin segregates lipid II into nonphysiological domains in vivo. (A) GUV containing 0.5 mole percent wild-type lipid II 15 min after the addition of fluorescently labeled vancomycin. (B) *B. megaterium* cells that were incubated for 10 min with labeled vancomycin (2 μ g/ml). The arrows point at newly formed division sites or older exemplars. (C) *B. subtilis* stained with fluorescent vancomycin (4 μ g/ml). (D) *B. megaterium* cells after incubation for 10 min with fluorescein-labeled nisin (0.5 μ g/ml). The arrow marks where the bacterium has already divided. (E) *B. subtilis* cells after incubation with fluorescein-labeled nisin (4 μ g/ml). The bottom image in (E) and the insets in (B) to (D) show Nomarski images.

